Hoffman Michael B
Known title: DirectorCIK: 0001290208
Hoffman Michael B's purchase track record
How the stock did after each of Hoffman Michael B's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
Purchases measured
5
of 6 since October 28, 2025
Stock higher 6 months later
0%
3 months: 33%
Median 6-month return
-48.7%
3 months: -12.3%
Beat the S&P 500
0%
median -61.8% vs. index
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 5/20/2026 | ANVS | $143K | -9.3% | pending | — |
| 4/2/2026 | ANVS | $1.50M | -15.3% | -48.7% | +16.5% |
| 12/8/2025 | ANVS | $194K | -40.2% | -58.4% | +8.2% |
| 11/24/2025 | ANVS | $160K | -41.6% | -49.6% | +12.1% |
| 11/14/2025 | ANVS | $102K | +1.3% | -12.0% | +10.0% |
| 10/28/2025 | ANVS | $2.00M | +38.1% | -11.9% | +3.6% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| ANVS | ▲ Buy | Open Market | 2,562 | $4K | 5/20/2026 | View on chart |
| ANVS | ▲ Buy | Open Market | 18,849 | $34K | 5/20/2026 | View on chart |
| ANVS | ▲ Buy | Open Market | 54,933 | $104K | 5/20/2026 | View on chart |
| ANVS | ▲ Buy | Open Market | 713,800 | $1.5M | 4/2/2026 | View on chart |
| ANVS | ▲ Buy | Open Market | 30,000 | $130K | 12/8/2025 | View on chart |
| ANVS | ▲ Buy | Open Market | 15,000 | $64K | 12/8/2025 | View on chart |
| ANVS | ▲ Buy | Open Market | 9,200 | $35K | 11/24/2025 | View on chart |
| ANVS | ▲ Buy | Open Market | 28,096 | $117K | 11/24/2025 | View on chart |
| ANVS | ▲ Buy | Open Market | 1,489 | $6K | 11/24/2025 | View on chart |
| ANVS | ▲ Buy | Open Market | 415 | $2K | 11/24/2025 | View on chart |
| ANVS | ▲ Buy | Open Market | 10,000 | $35K | 11/21/2025 | View on chart |
| ANVS | ▲ Buy | Open Market | 10,000 | $35K | 11/21/2025 | View on chart |
| ANVS | ▲ Buy | Open Market | 15,000 | $32K | 11/14/2025 | View on chart |
| ANVS | ▲ Buy | Open Market | 975,610 | $2.0M | 10/28/2025 | View on chart |
| ANVS | ▲ Buy | Grant | 5,000 | $12K | 8/29/2025 | View on chart |
| ANVS | ▲ Buy | Grant | 5,000 | $11K | 8/29/2025 | View on chart |
| ANVS | ▲ Buy | Grant | 5,000 | $11K | 8/29/2025 | View on chart |
| ANVS | ▲ Buy | Grant | 1,100 | $3K | 8/19/2025 | View on chart |
| ANVS | ▲ Buy | Grant | 5,283 | $14K | 8/19/2025 | View on chart |
| ANVS | ▲ Buy | Grant | 6,717 | $17K | 8/19/2025 | View on chart |
| ANVS | ▲ Buy | Grant | 5,545 | $14K | 8/19/2025 | View on chart |
| ANVS | ▲ Buy | Grant | 1 | $3 | 6/13/2025 | View on chart |
| ANVS | ▲ Buy | Grant | 25,000 | $70K | 6/13/2025 | View on chart |
| ANVS | ▲ Buy | Grant | 5,000 | $12K | 5/29/2025 | View on chart |
| ANVS | ▲ Buy | Grant | 164,745 | $1.0M | 11/20/2023 | View on chart |
| ANVS | ▲ Buy | Grant | 59,477 | $750K | 4/7/2023 | View on chart |
| ANVS | ▼ Sell | Tax Withholding | 6,658 | $132K | 1/4/2022 | View on chart |
| ANVS | ▲ Buy | Option Exercise | 7,142 | $2K | 1/4/2022 | View on chart |
| ANVS | ▼ Sell | Tax Withholding | 90 | $2K | 1/4/2022 | View on chart |
| ANVS | ▲ Buy | Option Exercise | 30,000 | $132K | 1/4/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 29, 2026
Annovis Bio Partners with Weave Bio for Alzheimer's NDA
Annovis Bio has announced a partnership with Weave Bio to use an AI regulatory platform. This collaboration is aimed at preparing the New Drug Application for buntanetap, a treatment for Alzheimer’s disease. The move supports the company's efforts to advance its lead candidate through the regulatory process.
Annovis Bio Partners with Weave Bio for Alzheimer's NDA. Annovis Bio has announced a partnership with Weave Bio to use an AI regulatory platform. This collaboration is aimed at preparing the New Drug Application for buntanetap, a treatment for Alzheimer’s disease. The move supports the company's efforts to advance its lead candidate through the regulatory process.